Share

R&D

Allergy Therapeutics R&DScientific and Clinical Research & Development

Mechanisms of Allergy

Allergy is thought to be caused by an imbalance between different parts of the immune system. The allergic reaction, which is characterised by inflammation and the production of antibodies involves several cell types and many different immune mediators.

Immunotherapy and Diagnostic Product Portfolio

Allergy Therapeutics has a long-term commitment to the research and development of innovative therapies for the diagnosis and treatment of allergy-related conditions. Allergy Therapeutics' current portfolio includes marketed and named patient products.

Subcutaneous immunotherapy

Subcutaneous immunotherapy formulations include combinations of allergens or allergoids (modified allergens) with tyrosine depot and MPL® adjuvant.

Allergoids

Allergy Therapeutics has long been at the forefront of innovation in the specific allergy vaccination field. It was the first company to introduce the chemical modification of the allergen extract to produce allergoids. These are purified allergen extracts which have been chemically treated to reduce the IgE reactivity whilst maintaining their IgG inducing profile.

L-Tyrosine formulated as Micro Crystalline Tyrosine (MCT) - Nature and Technology working in synergy

MCT is a patented preparation of the amino acid L-Tyrosine forming a dynamically degradable depot excipient. Because L-Tyrosine is required the body naturally has mechanisms for its metabolism, incorporation or excretion. That means the depot is completely bio-degraded once it has fulfilled its function as an essential amino acid. [1,2]

MPL® Adjuvant

Monophosphoryl lipid A (MPL®) is an immunological adjuvant that Allergy Therapeutics has licensed from GlaxoSmithKline. MPL® has demonstrable T helper cell activity and a suitably non-toxic profile in both animals and humans. [3,4]

MPL® and tyrosine synergy

Studies in which mice were injected with formulations containing both MPL® and tyrosine have shown that the induction of antibody response is indicative of a synergistic relationship between these components, with respect to the specific Th1 response. [5]

Orally Administered Vaccines

Allergy Therapeutics is developing a range of orally administered allergy vaccines comprising common allergens combined with MPL®. These vaccines could overcome the need for injections and lead the way for the widespread acceptance and administration of allergy vaccines. The possibility of self-administration and GP prescription provides patient convenience.

Patents

Allergy Therapeutics has a strong patent portfolio with the main product and technology development platforms being covered by patents, some of which have broad generic definitions. Allergy Therapeutics' policy has been to consolidate patents and to seek patent protection for new products and technology world-wide.

[1] Kramer MF, Heath MD. Vaccine. 2014 Jul 16; 32 (33): 4140-8. Aluminium in allergen-specific subcutaneous immunotherapy-a German perspective.

[2] Bell AJ, Heath MD, Hewings SJ & Skinner MA. 2015 Adsorption Consistency in Modified Allergen Tyrosine Adsorbed (MATA) Monophosphoryl Lipid A  Formulations for use in Allergy. Immunotherapy In press.

[3] Drachenberg KJ, Proell S, Urban E. 2002 Short-term immunotherapy using an allergy vaccine adjuvanted with Monophosphoryl lipid A: a post-marketing surveillance study" Allergologie 25: suppl. 2, 8-14 (text in German).

[4] Wheeler AW, Marshall JS & Ulrich JT. 2001 A Th1-Inducing Adjuvant, MPL®, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines. International Archives of Allergy & Immunology 126: 135-139.

[5] Wheeler AW. 2006 A novel adjuvant complex, tyrosine-MPL, for prophylatic and therapeutic vaccines. Vaccine 24 Suppl 2:S2-40-1.

Share